Monitoring Airway Disease 2019
DOI: 10.1183/13993003.congress-2019.oa5353
|View full text |Cite
|
Sign up to set email alerts
|

Characteristics of severe asthmatics treated with omalizumab, mepolizumab or no biotherapy. Data from the Belgian Severe Asthma Registry (BSAR)

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles